BioMerieux (LTS:0RUG) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 24, 2026)


LTS:0RUG BioMerieux SA LTS:0RUG
71 GF Score
Price €66.55
GF Value €109.89
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is BioMerieux Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

BioMerieux's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

LTS:0RUG vs TMO, DHR, IDXX: Margin of Safety % (DCF Earnings Based) Comparison

For the Diagnostics & Research subindustry, BioMerieux's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioMerieux Margin of Safety % (DCF Earnings Based) vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, BioMerieux's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where BioMerieux's Margin of Safety % (DCF Earnings Based) falls into.


LTS:0RUG
71GF Score
BioMerieux SA LTS:0RUG
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BioMerieux (LTS:0RUG) Overvalued in 2026?

Based on GuruFocus' analysis, BioMerieux stock appears to be undervalued. The current stock price of €66.55 is trading 39.4% below its estimated GF Value™ of €109.89. GuruFocus considers BioMerieux to be Significantly Undervalued.

Key valuation signals for LTS:0RUG:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €109.89 vs. price of €66.55 (39.4% below fair value)
  • GF Score™: 71/100 with 3 warning signs

No single metric tells the full story. See the LTS:0RUG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioMerieux Business Description

Address Marcy l’Etoile, Lyon, FRA, 69280
BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (42% of 2024 sales), microbiology (33%), immunoassays (10%), and industrial applications (about 15%). The Americas account for the largest portion of the firm's revenue (40%), followed by Asia-Pacific (27%) and Europe, the Middle East, and Africa (27%). BioMérieux is headquartered in Marcy-l'Étoile, France.
71GF Score

Get the complete analysis for LTS:0RUG

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€66.55
Price
€109.89
GF Value